Anatomy Physiology Biochem Pathology Pharmacology Microbiology forensic Ophthalmology E N T Medicine Gynaecology Obstetrics surgery Paediatrics and many more subject's lecture notes ONLINE.
Search Medical Lecture Notes
medicalpptonline.blogspot.com contains lecture notes in most fields of medicine. You can directly copy lectures to your laptop ,no need of downloading or streaming
Lectures are collected from various sources.I will not be responsible for any typing error and out dated medical facts.Visitors are advised to cross check the information
Please give the authors the credit they deserve and do not change the author's name
If any of of you have a good personal power point presentations Email me i will upload it here.
Lectures are collected from various sources.I will not be responsible for any typing error and out dated medical facts.Visitors are advised to cross check the information
Please give the authors the credit they deserve and do not change the author's name
If any of of you have a good personal power point presentations Email me i will upload it here.
Breast Cancer
Risk Factors
§ Age >50
§ Family History
§ LCIS or atypical hyperplasia
§ Dense breast tissue
§ BRCA mutation
Types
Invasive
Ductal
Lobular
Mucinous
Tubular
Non-invasive
DCIS (does not metastasize)
Diagnosis
§ Mammogram is a SCREENING TOOL
§ FNA
§ Excisional Bx
§ Core Bx
§ Sterotactic BX
Who to MRI?
§ Known BRCA mutation
§ First degree relative with BRCA mutation
§ 20% risk based on validated model (BRACA-Pro)
§ Other familial syndrome
§ Cowden, Li-Fraummeni, HNPCC
§ Hx of chest wall RT btwn 10-30yr of age
§ e.g. Hodgkins disease
Treatment
§ Surgical Treatment
§ Mastectomy
§ Breast conversation
§ Lumpectomy with XRT
Hormonal Treatment
§ ER, PR, Her 2 nu status
§ Adjunct therapy to minimize risk of recurrence
§ Tamoxifen
§ Aromatase inhibitor (Irimidex)
§ Herceptin
Survival -/+ adjuvant tx
§ T1a: 95% 96%
§ T1b: 90% 93%
§ T1c: 80% 86.5%
§ T2aN0: 70% 80%
§ T2bN1: 60% 73%
§ T3aN0: 70% 80%
§ T3bN1: 40% 60%
§ TXNXM1: <5% at 5 years
Tamoxifen
§ 5 yrs duration (newer data to support 10)
§ Decreases recurrence risk by 37-54%
§ Increases overall survival by 11-34%
§ Monitor for development of endometrial cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment